IceCure Medical Regains Nasdaq Compliance
Ticker: ICCM · Form: 6-K · Filed: Jan 6, 2025 · CIK: 1584371
Sentiment: bullish
Topics: compliance, nasdaq, listing
Related Tickers: ICCM
TL;DR
IceCure Medical is back in Nasdaq's good graces, keeping its stock listed.
AI Summary
On January 6, 2025, IceCure Medical Ltd. announced it has regained full compliance with the Nasdaq Stock Market's minimum closing bid price rule. This compliance is crucial for maintaining its listing on the Nasdaq Capital Market.
Why It Matters
Regaining Nasdaq compliance is essential for IceCure Medical to maintain its stock listing, which is vital for investor confidence and future fundraising.
Risk Assessment
Risk Level: low — The filing is a routine announcement of compliance with exchange rules, indicating a positive development with no immediate new risks.
Key Players & Entities
- IceCure Medical Ltd. (company) — The company filing the report and announcing compliance.
- Nasdaq (company) — The stock exchange where IceCure Medical is listed and whose rules were complied with.
- January 6, 2025 (date) — The date of the press release and the filing.
FAQ
What specific rule did IceCure Medical comply with?
IceCure Medical regained compliance with the Nasdaq Stock Market's minimum closing bid price rule.
When was this compliance announced?
The announcement was made on January 6, 2025.
What is the significance of regaining Nasdaq compliance?
Regaining compliance is crucial for IceCure Medical to maintain its listing on the Nasdaq Capital Market.
What form is this filing?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Where is IceCure Medical's principal executive office located?
IceCure Medical's principal executive office is located at 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel.
Filing Stats: 297 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-01-06 08:40:01
Filing Documents
- ea0226841-6k_icecure.htm (6-K) — 11KB
- ea022684101ex99-1_icecure.htm (EX-99.1) — 7KB
- 0001213900-25-000955.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: January 6, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2